S&P 500   3,986.27 (+0.38%)
DOW   32,484.20 (+0.77%)
QQQ   308.79 (-0.68%)
AAPL   158.38 (-1.17%)
MSFT   276.25 (-1.54%)
META   202.42 (-1.74%)
GOOGL   102.41 (-2.87%)
AMZN   97.41 (-0.73%)
TSLA   191.71 (+0.68%)
NVDA   265.83 (-0.73%)
NIO   8.92 (-1.65%)
BABA   85.69 (-1.39%)
AMD   96.40 (-1.58%)
T   18.90 (+1.56%)
F   11.52 (+0.09%)
MU   60.01 (-1.88%)
CGC   1.89 (-0.54%)
GE   93.40 (+2.22%)
DIS   95.27 (+1.26%)
AMC   4.40 (-1.57%)
PFE   40.35 (-0.10%)
PYPL   73.47 (-0.55%)
NFLX   325.91 (-0.76%)
S&P 500   3,986.27 (+0.38%)
DOW   32,484.20 (+0.77%)
QQQ   308.79 (-0.68%)
AAPL   158.38 (-1.17%)
MSFT   276.25 (-1.54%)
META   202.42 (-1.74%)
GOOGL   102.41 (-2.87%)
AMZN   97.41 (-0.73%)
TSLA   191.71 (+0.68%)
NVDA   265.83 (-0.73%)
NIO   8.92 (-1.65%)
BABA   85.69 (-1.39%)
AMD   96.40 (-1.58%)
T   18.90 (+1.56%)
F   11.52 (+0.09%)
MU   60.01 (-1.88%)
CGC   1.89 (-0.54%)
GE   93.40 (+2.22%)
DIS   95.27 (+1.26%)
AMC   4.40 (-1.57%)
PFE   40.35 (-0.10%)
PYPL   73.47 (-0.55%)
NFLX   325.91 (-0.76%)
S&P 500   3,986.27 (+0.38%)
DOW   32,484.20 (+0.77%)
QQQ   308.79 (-0.68%)
AAPL   158.38 (-1.17%)
MSFT   276.25 (-1.54%)
META   202.42 (-1.74%)
GOOGL   102.41 (-2.87%)
AMZN   97.41 (-0.73%)
TSLA   191.71 (+0.68%)
NVDA   265.83 (-0.73%)
NIO   8.92 (-1.65%)
BABA   85.69 (-1.39%)
AMD   96.40 (-1.58%)
T   18.90 (+1.56%)
F   11.52 (+0.09%)
MU   60.01 (-1.88%)
CGC   1.89 (-0.54%)
GE   93.40 (+2.22%)
DIS   95.27 (+1.26%)
AMC   4.40 (-1.57%)
PFE   40.35 (-0.10%)
PYPL   73.47 (-0.55%)
NFLX   325.91 (-0.76%)
S&P 500   3,986.27 (+0.38%)
DOW   32,484.20 (+0.77%)
QQQ   308.79 (-0.68%)
AAPL   158.38 (-1.17%)
MSFT   276.25 (-1.54%)
META   202.42 (-1.74%)
GOOGL   102.41 (-2.87%)
AMZN   97.41 (-0.73%)
TSLA   191.71 (+0.68%)
NVDA   265.83 (-0.73%)
NIO   8.92 (-1.65%)
BABA   85.69 (-1.39%)
AMD   96.40 (-1.58%)
T   18.90 (+1.56%)
F   11.52 (+0.09%)
MU   60.01 (-1.88%)
CGC   1.89 (-0.54%)
GE   93.40 (+2.22%)
DIS   95.27 (+1.26%)
AMC   4.40 (-1.57%)
PFE   40.35 (-0.10%)
PYPL   73.47 (-0.55%)
NFLX   325.91 (-0.76%)
NASDAQ:XBIO

Xenetic Biosciences - XBIO Stock Forecast, Price & News

$0.42
+0.03 (+7.65%)
(As of 03/27/2023 01:18 PM ET)
Add
Compare
Today's Range
$0.39
▼
$0.43
50-Day Range
$0.35
▼
$0.73
52-Week Range
$0.24
▼
$1.25
Volume
66,576 shs
Average Volume
60,138 shs
Market Capitalization
$6.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

Xenetic Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
918.1% Upside
$4.00 Price Target
Short Interest
Healthy
0.26% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.19mentions of Xenetic Biosciences in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.28) to ($0.39) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.84 out of 5 stars

See Top Rated MarketRank™ Stocks Here

XBIO stock logo

About Xenetic Biosciences (NASDAQ:XBIO) Stock

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

Receive XBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xenetic Biosciences and its competitors with MarketBeat's FREE daily newsletter.

XBIO Stock News Headlines

March 16, 2023 | finanznachrichten.de
JTC Team, LLC: JTC Team to Host Virtual Investor NETs in Cancer Spotlight Event Featuring Xenetic Biosciences
March 16, 2023 | finance.yahoo.com
JTC Team to Host Virtual Investor NETs in Cancer Spotlight Event Featuring Xenetic Biosciences
March 27, 2023 | Oxford Club (Ad)
My No. 1 dividend stock for a LIFETIME of income.
Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century!  I think it's a crying shame folks don't know how powerful dividends are.
February 23, 2023 | seekingalpha.com
XBIO Xenetic Biosciences, Inc.
February 21, 2023 | reuters.com
XBIO.PH - | Stock Price & Latest News | Reuters
January 17, 2023 | finance.yahoo.com
Xenetic Biosciences, Inc. Announces Notice of Allowance for Canadian Patent Covering Use of DNase Enzyme for Preventing or Ameliorating Toxicity Associated with Chemotherapy
December 15, 2022 | finance.yahoo.com
Why We Think Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Is Not Excessive At All
December 1, 2022 | finance.yahoo.com
This Is Why Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Looks Appropriate
March 27, 2023 | Oxford Club (Ad)
My No. 1 dividend stock for a LIFETIME of income.
Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century!  I think it's a crying shame folks don't know how powerful dividends are.
November 12, 2022 | finance.yahoo.com
Xenetic Biosciences Third Quarter 2022 Earnings: Beats Expectations
September 7, 2022 | finance.yahoo.com
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference
August 12, 2022 | finance.yahoo.com
Xenetic Biosciences, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update
June 2, 2022 | finance.yahoo.com
Xenetic Biosciences, Inc. to Participate in the Virtual Investor Innovation in Oncology Event
May 18, 2022 | finance.yahoo.com
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright Global Investment Conference
May 12, 2022 | seekingalpha.com
Xenetic Biosciences reports Q1 results
May 12, 2022 | finance.yahoo.com
Xenetic Biosciences, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update
May 2, 2022 | benzinga.com
HC Wainwright & Co. Maintains Buy on Xenetic Biosciences, Lowers Price Target to $4
May 2, 2022 | proactiveinvestors.com
Xenetic Biosciences expands pipeline with DNase based oncology platform from CLS Therapeutics
April 27, 2022 | seekingalpha.com
Xenetic stock rises 10% on license deal for CLS Therapeutics' cancer drugs platform
April 27, 2022 | finance.yahoo.com
Xenetic Biosciences, Inc. Expands Oncology Pipeline with In-Licensing of DNase Based Oncology Platform Comprising Multiple Therapeutic Modalities
March 24, 2022 | morningstar.com
Xenetic Biosciences, Inc. Reports Full Year 2021 Financial Results and Provides Business Update | Morningstar
March 23, 2022 | seekingalpha.com
Xenetic Biosciences GAAP EPS of -$0.55, revenue of $1.16M
March 23, 2022 | finance.yahoo.com
Xenetic Biosciences, Inc. Reports Full Year 2021 Financial Results and Provides Business Update
December 11, 2021 | benzinga.com
'We are expanding the potential of CAR T cell therapy through the development of our XCART technology platform...' -Tweet From Xenetic Biosciences
November 12, 2021 | finance.yahoo.com
Xenetic Biosciences, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update
November 4, 2021 | finance.yahoo.com
Analysts Estimate Xenetic Biosciences (XBIO) to Report a Decline in Earnings: What to Look Out for
October 15, 2021 | msn.com
BRIEF-Xenetic Biosciences Amended Agreement With Pharmsynthez To Terminate All Agreement Work Orders
See More Headlines
Receive XBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xenetic Biosciences and its competitors with MarketBeat's FREE daily newsletter.

XBIO Company Calendar

Last Earnings
11/11/2021
Today
3/27/2023
Next Earnings (Estimated)
5/11/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:XBIO
CUSIP
N/A
CIK
1534525
Web
www.xeneticbio.com
Phone
781-778-7720
Fax
N/A
Employees
4
Year Founded
2011

Price Target and Rating

Average Stock Price Forecast
$4.00
High Stock Price Forecast
$4.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+920.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.47)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-5,640,000.00
Net Margins
-383.89%
Pretax Margin
-383.83%
Return on Equity
-43.49%
Return on Assets
-40.49%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
12.72
Quick Ratio
13.48

Sales & Book Value

Annual Sales
$1.71 million
Price / Sales
3.48
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.37 per share
Price / Book
0.29

Miscellaneous

Outstanding Shares
15,170,000
Free Float
14,029,000
Market Cap
$5.95 million
Optionable
Not Optionable
Beta
2.77

Social Links


Key Executives

  • Mr. Jeffrey F. Eisenberg (Age 53)
    CEO & Director
  • Mr. James F. Parslow (Age 54)
    CFO, COO & Corp. Sec.
  • Dr. Curtis A. Lockshin (Age 59)
    Chief Scientific Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













XBIO Stock - Frequently Asked Questions

Should I buy or sell Xenetic Biosciences stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Xenetic Biosciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" XBIO shares.
View XBIO analyst ratings or view top-rated stocks.

What is Xenetic Biosciences' stock price forecast for 2023?

1 analysts have issued 12 month price objectives for Xenetic Biosciences' stock. Their XBIO share price forecasts range from $4.00 to $4.00. On average, they expect the company's share price to reach $4.00 in the next year. This suggests a possible upside of 920.4% from the stock's current price.
View analysts price targets for XBIO or view top-rated stocks among Wall Street analysts.

How have XBIO shares performed in 2023?

Xenetic Biosciences' stock was trading at $0.2851 at the beginning of 2023. Since then, XBIO stock has increased by 37.5% and is now trading at $0.3920.
View the best growth stocks for 2023 here.

When is Xenetic Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023.
View our XBIO earnings forecast.

How were Xenetic Biosciences' earnings last quarter?

Xenetic Biosciences Inc (NASDAQ:XBIO) announced its quarterly earnings data on Thursday, November, 11th. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by $0.01. The firm earned $0.35 million during the quarter, compared to analysts' expectations of $0.20 million. Xenetic Biosciences had a negative net margin of 383.89% and a negative trailing twelve-month return on equity of 43.49%.

What other stocks do shareholders of Xenetic Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xenetic Biosciences investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Biocept (BIOC), Trevena (TRVN), TherapeuticsMD (TXMD), T2 Biosystems (TTOO), Vaxart (VXRT), Aytu BioPharma (AYTU) and Co-Diagnostics (CODX).

What is Xenetic Biosciences' stock symbol?

Xenetic Biosciences trades on the NASDAQ under the ticker symbol "XBIO."

Who are Xenetic Biosciences' major shareholders?

Xenetic Biosciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.95%).

How do I buy shares of Xenetic Biosciences?

Shares of XBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Xenetic Biosciences' stock price today?

One share of XBIO stock can currently be purchased for approximately $0.39.

How much money does Xenetic Biosciences make?

Xenetic Biosciences (NASDAQ:XBIO) has a market capitalization of $5.95 million and generates $1.71 million in revenue each year. The company earns $-5,640,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis.

How can I contact Xenetic Biosciences?

Xenetic Biosciences' mailing address is 40 Speen Street Suite 102, Framingham MA, 01701. The official website for the company is www.xeneticbio.com. The company can be reached via phone at 781-778-7720 or via email at xbio@jtcir.com.

This page (NASDAQ:XBIO) was last updated on 3/27/2023 by MarketBeat.com Staff